Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891784 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
A Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT03891784: Active Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm, sponsored by University of Washington.
NCT03891784 is a Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 20 participants, below the 118-participant average among 7 other Pancreatic Neuroendocrine Tumor trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03891784, a Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
ORR defined as complete or partial response as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, will be represented by a waterfall plot.
Conditions Studied
Interventions
- DRUG Abemaciclib
Study Locations (2)
Colorado
- University of Colorado - Denver
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT03891784 still lists
NCT03891784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 118-participant average among 7 other Pancreatic Neuroendocrine Tumor trials with a reported enrollment target (83% lower).
The record links to 9 conditions, with Pancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib is the first listed.
NCT03891784 reports a single indexed study location in Colorado, Washington.
Frequently Asked Questions
What is clinical trial NCT03891784 about?
NCT03891784 is a clinical study titled "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors". This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the ...
What is the current status of trial NCT03891784?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-10-31. Estimated completion is 2026-07.
What conditions does trial NCT03891784 study?
This clinical trial studies the following conditions: Pancreatic Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor.
What interventions are being tested in trial NCT03891784?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT03891784?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03891784 being conducted?
This trial has 2 study locations across Colorado, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 2
-
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI